-

10:22:40 AM

PALI Stock News

PALI - Palisade Bio Inc

06/01/23 8:45 AM

Nasdaq : PALI

low float

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley has been named Chief Executive Officer

RHEA-AI

neutral

05/24/23 8:45 AM

Nasdaq : PALI

clinical triallow float

Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”

RHEA-AI

neutral

05/12/23 8:05 AM

Nasdaq : PALI

earningslow float

Palisade Bio Reports First Quarter 2023 Financial Results

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today

RHEA-AI

neutral

05/11/23 9:05 AM

Nasdaq : PALI

low float

Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Palisade Bio, Inc. (Nasdaq: PALI)

RHEA-AI

neutral

04/06/23 9:00 AM

Nasdaq : PALI

low float

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property Office (CIPO) has issued Canadian

RHEA-AI

neutral

04/05/23 8:35 AM

Nasdaq : PALI

clinical triallow float

Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today

RHEA-AI

neutral

04/03/23 8:30 AM

Nasdaq : PALI

offeringlow float

Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the

RHEA-AI

neutral

03/23/23 8:05 AM

Nasdaq : PALI

earningslow float

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the

RHEA-AI

neutral

03/01/23 9:05 AM

Nasdaq : PALI

low float

Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent

Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that European Patent Office (EPO) has issued a notice of

RHEA-AI

positive

02/08/23 8:35 AM

Nasdaq : PALI

low float

Palisade Bio Promotes Robert McRae to Chief Operating Officer

Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

PALI Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.palisadebio.com
CeoKenneth Carter
Security namePalisade Bio Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees12
Address20271 Goldenrod Ln Ste 2024
StateMaryland
CityGermantown
Zip20876
CountryUS
Phone13013664841

About Palisade Bio Inc

Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.